<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8673">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02994043</url>
  </required_header>
  <id_info>
    <org_study_id>16-0056</org_study_id>
    <nct_id>NCT02994043</nct_id>
  </id_info>
  <brief_title>Mindfulness Based Relapse Prevention</brief_title>
  <acronym>AIM</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Boulder</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Boulder</source>
  <brief_summary>
    <textblock>
      The goal of the AIM Study is to examine the effectiveness of Mindfulness Based Relapse
      Prevention (MBRP) versus Relapse Prevention (RP) for the treatment of Alcohol Use Disorders
      (AUD) by implementing an 8-week long intervention and examining neurobiological,
      immunological, and epigenetic characteristics of AUD.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of heavy drinking days</measure>
    <time_frame>4, 8, 20, and 32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in methylation of key genes involved in Alcohol Use Disorders</measure>
    <time_frame>4, 8, 20, and 32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in inflammation biomarkers</measure>
    <time_frame>4, 8, 20, and 32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Left and Right Executive Control Network (LECN and RECN) connectivity detected by MRI</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood-oxygen level dependent (BOLD) activation detected by MRI</measure>
    <time_frame>32 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in gut microbiota populations</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Alcohol Use Disorder</condition>
  <arm_group>
    <arm_group_label>MBRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 weeks of mindfulness therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>8 weeks of traditional therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Mindfulness Plus Relapse Prevention Therapy</intervention_name>
    <arm_group_label>MBRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Relapse Prevention Therapy</intervention_name>
    <arm_group_label>RP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a primary Diagnostic Statistical Manual-V (DSM-V) diagnosis of alcohol use
             disorder;

          2. Must be within 10 days of last drink;

          3. Must have been drinking heavily (criteria dependent upon individual's age, gender,
             and BMI) for a consistent period of time;

          4. Must have a breath alcohol level of 0 at screening;

          5. Must have a Clinical Institute Withdrawal Assessment (CIWA) score less than 8
             (indicating no need for medical detox);

          6. Must have expressed a desire during their initial screen to reduce the number of
             drinks they regularly consume

        Exclusion Criteria:

          1. Currently taking any medications for the treatment of psychiatric disorders,
             including substance use disorders, mood disorders, and psychosis;

          2. Pregnant, as indicated by a pregnancy test which will be administered at baseline;

          3. Positive for, sedatives, opiates, cocaine, or amphetamine on drug screen at baseline;

          4. Meets criteria for psychotic disorder, bipolar disorder, or a major depressive
             episode
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kent Hutchison, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Boulder</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claire Koljack, B.A.</last_name>
    <phone>303-735-1304</phone>
    <email>claire.koljack@colorado.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Raeghan Mueller, B.A.</last_name>
    <phone>303-492-9549</phone>
    <email>raeghan.mueller@colorado.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CU CHANGE Lab</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent Hutchison, Ph.D.</last_name>
      <email>kent.hutchison@colorado.edu</email>
    </contact>
    <contact_backup>
      <last_name>Claire Koljack, B.A.</last_name>
      <phone>303-492-9549</phone>
      <email>claire.koljack@colorado.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 12, 2016</lastchanged_date>
  <firstreceived_date>December 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
